牛牛AI助理已提取核心訊息
John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 24, 2024, involving the acquisition of 29 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 141 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.
John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 24, 2024, involving the acquisition of 29 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 141 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.
T2 Biosystems, Inc.（TTOO）首席財務官約翰·斯普拉格於2024年2月24日執行了一項交易，涉及收購29股普通股。該交易被歸類爲 “M”，表示行使或轉換衍生證券。在這筆交易之後，Sprague在該公司的直接持有量增加到總共141股普通股。該行動反映了首席財務官對該公司的持續投資，這表明了對T2 Biosystems未來業績的潛在信心。
T2 Biosystems, Inc.（TTOO）首席財務官約翰·斯普拉格於2024年2月24日執行了一項交易，涉及收購29股普通股。該交易被歸類爲 “M”，表示行使或轉換衍生證券。在這筆交易之後，Sprague在該公司的直接持有量增加到總共141股普通股。該行動反映了首席財務官對該公司的持續投資，這表明了對T2 Biosystems未來業績的潛在信心。
有用
沒用
